Patents by Inventor Rebecca M. Lui

Rebecca M. Lui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
    Patent number: 11866429
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 9, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Processes and intermediates in the preparation of C5aR antagonists
    Patent number: 11845729
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: December 19, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • CXCR7 antagonists
    Patent number: 11834452
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: December 5, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • CCR4 ANTAGONISTS
    Publication number: 20230382894
    Abstract: Compounds are provided having formula (I): wherein the groups/letters R1a, R1b, m, R2, R3, R4, X, Y, A, B, n, q, L and Q, have the meanings provided herein. The compounds are useful as CCR4 antagonists and are useful in treated diseases and conditions modulated by CCR4 activity.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 30, 2023
    Inventors: Pingchen FAN, Rebecca M. LUI, Ryan J. SCAMP, Ju YANG, Yu WANG, Yibin ZENG, Penglie ZHANG
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20230381167
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 30, 2023
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • Deuterated compounds as immunomodulators
    Patent number: 11807609
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 7, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES
    Publication number: 20230322731
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 12, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • 6-5 fused rings as C5a inhibitors
    Patent number: 11773091
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 3, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
    Patent number: 11713307
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: August 1, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • 6-5 FUSED RINGS AS C5a INHIBITORS
    Publication number: 20230151002
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: May 3, 2022
    Publication date: May 18, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors
    Publication number: 20230133406
    Abstract: Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Application
    Filed: August 17, 2022
    Publication date: May 4, 2023
    Inventors: Penglie ZHANG, Daniel R. MARSHALL, Howard S. ROTH, Aubrie HARLAND, Ju YANG, Christopher W. LANGE, Rebecca M. LUI, Antoni KRASINSKI
  • 2-OXINDOLE COMPOUNDS
    Publication number: 20230119895
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: August 1, 2022
    Publication date: April 20, 2023
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • Prodrugs of fused-bicyclic C5aR antagonists
    Patent number: 11608336
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: March 21, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Rajinder Singh, Venkat Reddy Mali, Yibin Zeng, Penglie Zhang
  • Amorphous form of a complement component C5a receptor
    Patent number: 11603356
    Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: March 14, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Kwok Yau, Kenken Luong, Rajinder Singh, Yibin Zeng, Penglie Zhang, Manmohan Reddy Leleti, Rebecca M. Lui
  • PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
    Publication number: 20230008966
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Application
    Filed: February 8, 2022
    Publication date: January 12, 2023
    Inventors: Pingchen FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Rebecca M. LUI, Jay POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS
    Publication number: 20220348568
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 18, 2022
    Publication date: November 3, 2022
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
    Patent number: 11485737
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: November 1, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • 5-5 fused rings as C5a inhibitors
    Patent number: 11479553
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Yibin Zeng, Penglie Zhang
  • 2-oxindole compounds
    Patent number: 11434230
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: September 6, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Salt forms of a complement component C5A receptor
    Patent number: 11427541
    Abstract: Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 30, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Ju Yang, Howard S. Roth